NCT02472145: A reported trial by Janssen Research & Development, LLC
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT02472145 |
|---|---|
| Title | A Randomized Phase 2/3 Study of DACOGEN® (Decitabine) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus DACOGEN (Decitabine) Alone in Patients With AML Who Are Not Candidates for Intensive Chemotherapy |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Aug. 4, 2015 |
| Completion date | Jan. 25, 2018 |
| Required reporting date | Jan. 25, 2019, midnight |
| Actual reporting date | Jan. 24, 2019 |
| Date last checked at ClinicalTrials.gov | March 26, 2026 |
| Days late | None |